Kala Pharmaceuticals (NASDAQ: KALA) reported Q1 EPS of ($0.75), in-line with the analyst estimate of ($0.75). Revenue for the quarter came in at $1.39 million versus the consensus estimate of $1.1 million.

“We are pleased with our results during the first quarter of 2019, particularly as it relates to the launch of INVELTYS,” said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. “We have received feedback from physicians that INVELTYS has been a meaningful addition to their treatment protocols for inflammation and pain following ocular surgery. Our team has made significant progress in securing market access for INVELTYS, and initial prescription uptake has been strong. We also continue to advance KPI-121 0.25% for dry eye disease, with an August 15 Prescription Drug User Fee Act (PDUFA) target action date and topline data from STRIDE 3 expected in the fourth quarter of 2019.”

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.